Beneficial effects of L-carnitine in myoblastic C2C12 cells: Interaction with zidovudine

Biochemical Pharmacology

Volumn 65, Issue 9, 2003, Pages 1483-1488

  Georges, Béatrice ^a   Galland, Stéphane ^a   Rigault, Caroline ^a   Le Borgne, Françoise ^a   Demarquoy, Jean ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

C2C12; L Carnitine; Lipid metabolism; Skeletal muscle; Transporter; Zidovudine

Indexed keywords

CARNITINE; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; BIOAVAILABILITY; BIOSYNTHESIS; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS; INTESTINE ABSORPTION; MITOCHONDRIAL MEMBRANE; MOUSE; MUSCLE FIBER MEMBRANE; MYOBLAST; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0037727758     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00110-2     Document Type: Article

References (17)

1. Duran J.M., Peral M.J., Calonge M.L., Ilundiin A.A. Functional characterization of intestinal L-carnitine transport. J. Membr. Biol. 185:2002;65-74.
2. Siliprandi N., Sartorelli L., Ciman M., Di Lisa F. Carnitine: metabolism and clinical chemistry. Clin. Chim. Acta. 183:1989;3-11.
3. Wu X., Prasad P.D., Leibach F.H., Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem. Biophys. Res. Commun. 246:1998;589-595.
4. Dalakas M.C., Leon-Monzon M.E., Bernardini I., Gahl W.A., Jay C.A. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann. Neurol. 35:1994;482-487.
5. Yaffe D., Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 270:1977;725-727.
6. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:2000;685-708.
7. Brinkman K., Ter Hofstede H.J., Burger D.M., Smeitink J.A., Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 12:1998;1735-1744.
8. Carr A., Cooper D.A. Adverse effects of antiretroviral therapy. Lancet. 356:2000;1423-1430.
9. Carr A., Miller J., Law M., Cooper D.A. A syndrome of lipoatrophy lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14:2000;F25-F32.
10. Mhiri C., Baudrimont M., Bonne G., Geny C., Degoul F., Marsacc Roullet E., Gherardi R. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann. Neurol. 29:1991;606-614.
11. Chariot P., Gherardi R. Partial cytochrome c oxidase deficiency and cytoplasmic bodies in patients with zidovudine myopathy. Neuromuscul. Disord. 1:1991;357-363.
12. Chariot P., Monnet I., Mouchet M., Rohr M., Lefaucheur J.P., Dubreuil-Lemaire M.L., Chousterman M., Gherardi R. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum. 37:1994;583-586.
13. Arnaudo E., Dalakas M., Shanske S., Moraes C.T., Dimauro S., Schon E.A. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 337:1991;508-510.
14. Semino-Mora M.C., Leon-Monzon M.E., Dalakas M.C. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Lab. Invest. 71:1994;102-112.
15. Georges B., Le Borgne F., Galland S., Isoir M., Ecosse D., Grand-Jean F., Demarquoy J. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Biochem. Pharmacol. 59:2000;1357-1363.
16. Shennan D.B., Grant A., Ramsay R.R., Burns C., Zammit V.A. Characteristics of L-carnitine transport by lactating rat mammary tissue. Biochim. Biophys. Acta. 1393:1998;49-56.
17. Benbrik E., Chariot P., Bonavaud S., Ammi-Said M., Frisdal E., Rey C., Gherardi R., Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci. 149:1997;19-25.